戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1    Screening for colorectal cancer by use of guaiac-based faecal occult blood tests (FOBT) reduces di
2 blood test age 40-75 years, 3) gFOBT: annual guaiac-based fecal occult blood test age 40-75 years, an
3 scopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunoch
4 te, or not at all to screening with biennial guaiac-based fecal occult blood test.
5 h multiple rounds of biennial screening with guaiac-based fecal occult blood testing (n = 419,966) sh
6 l immunochemical testing or high-sensitivity guaiac-based fecal occult blood testing every 2 years, c
7                     Screening with sensitive guaiac-based fecal occult blood testing, fecal immunoche
8 tinal tract can cause a positive reaction on guaiac-based fecal occult-blood tests, the relative freq
9 emical testing exhibits some advantages over guaiac-based testing.
10 es from each of three consecutive stools for guaiac-based testing.
11  Fecal occult blood was detected by standard guaiac-based tests of stool specimens obtained as part o
12                           Annual or biennial guaiac fecal occult blood test (gFOBT) vs no screening (
13 marily detect early cancer include sensitive guaiac fecal occult blood test or fecal immunochemical t
14  screened for colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop
15 copy every 10 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal
16 screening appears to be lower than that with guaiac fecal occult blood testing.
17 s received only FIT (1594 received FIT after guaiac FOBT and 2022 received FIT after FIT).
18  correlation between degree of positivity on guaiac FOBT and on immunochemical FOBT (p<0.003).
19 city, about half of individuals positive for guaiac FOBT are negative for neoplasia on colonoscopy.
20 ochemical FOBT for individuals with positive guaiac FOBT could decrease substantially the number of f
21 ther the testing of individuals positive for guaiac FOBT in a screening programme for colorectal canc
22 h a previous negative test result (FIT after guaiac FOBT or FIT after FIT) and first-round participan
23 FIT after FIT) and first-round participants (guaiac FOBT or FIT).
24 andomly assigned to groups that received the guaiac FOBT or FIT.
25              We invited individuals who were guaiac FOBT positive in the second screening round of a
26 gard to sex, age, or degree of positivity on guaiac FOBT.
27  patients with total villous atrophy using a guaiac-impregnated card (Hemoccult).
28 uration of the left, normal rectal tone, and guaiac-negative stool.
29 lts after a positive result on a fecal test (guaiac or immunochemical).
30 on by occult rectal bleeding was excluded by guaiac paper test.
31 n by occult rectal bleeding was ruled out by guaiac paper test.
32  or absent, and in no case did stools become guaiac-positive.
33 ples each) FITs, as well as the Hemoccult II guaiac test (SKD, Villepinte, France) (3 samples each).
34 m the FITs were compared with those from the guaiac test for cut-off values for stool samples, positi
35                  Hemoccult II, a widely used guaiac test for fecal occult blood, has a low sensitivit
36                 Despite the low costs of the guaiac test, the high false positives and high false neg
37 ult II; Hemoccult II Sensa, a more sensitive guaiac test; and HemeSelect, an immunochemical test for
38 uced specificity occur with high-sensitivity guaiac tests and fecal DNA, with other important uncerta
39                            At the same time, guaiac tests suffer from poor sensitivity, limited abili
40  cancer with greater levels of accuracy than guaiac tests.